Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C128625> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- NCIT_C128625 IAO_0000115 "A humanized, bivalent anti-von Willebrand factor (VWF) nanobody, with potential anti-platelet and anti-thrombotic activities. Upon administration, caplacizumab specifically binds, with its two identical monovalent moieties, to the A1 domain of the adhesive glycoprotein VWF, thereby inhibiting and neutralizing VWF activity. This prevents the interaction of ultra-large VWF (ULVWF) with the platelet glycoprotein (GP)Ib-IX-V receptor complex, and prevents ULVWF-mediated platelet adhesion, and aggregation, which reduces thrombus formation. VWF is a glycoprotein and plays a key role in blood coagulation. Increased VWF, which is seen in a number of diseases, is associated with an increased risk in thrombosis; in thrombotic thrombocytopenic purpura (TTP), increased levels of ULVWF and thus increased and abnormal platelet aggregation are seen due to impaired breakdown of ULVWF. The nanobody formulation allows for rapid distribution, onset of action and clearance. The nanobody is based on the smallest functional fragments of the immunoglobulin heavy-chain variable domains that occur naturally in the Camelidae family." @default.
- NCIT_C128625 NCIT_NHC0 "C128625" @default.
- NCIT_C128625 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C128625 NCIT_P107 "Caplacizumab" @default.
- NCIT_C128625 NCIT_P108 "Caplacizumab" @default.
- NCIT_C128625 NCIT_P207 "C3713057" @default.
- NCIT_C128625 NCIT_P210 "915810-67-2" @default.
- NCIT_C128625 NCIT_P302 "acquired thrombotic thrombocytopenic purpura (aTTP)" @default.
- NCIT_C128625 NCIT_P319 "2R27AB6766" @default.
- NCIT_C128625 NCIT_P322 "CTRP" @default.
- NCIT_C128625 NCIT_P322 "FDA" @default.
- NCIT_C128625 NCIT_P329 "782660" @default.
- NCIT_C128625 NCIT_P330 "782660" @default.
- NCIT_C128625 NCIT_P399 "782660" @default.
- NCIT_C128625 normalizedInformationContent "100" @default.
- NCIT_C128625 referenceCount "1" @default.
- NCIT_C128625 hasExactSynonym "ALX 0081" @default.
- NCIT_C128625 hasExactSynonym "ALX 0681" @default.
- NCIT_C128625 hasExactSynonym "ALX-0081" @default.
- NCIT_C128625 hasExactSynonym "ALX-0681" @default.
- NCIT_C128625 hasExactSynonym "ALX0081" @default.
- NCIT_C128625 hasExactSynonym "ALX0681" @default.
- NCIT_C128625 hasExactSynonym "CAPLACIZUMAB" @default.
- NCIT_C128625 hasExactSynonym "Cablivi" @default.
- NCIT_C128625 hasExactSynonym "Caplacizumab" @default.
- NCIT_C128625 hasExactSynonym "Caplacizumab-yhdp" @default.
- NCIT_C128625 inSubset NCIT_C116977 @default.
- NCIT_C128625 inSubset NCIT_C116978 @default.
- NCIT_C128625 inSubset NCIT_C176424 @default.
- NCIT_C128625 inSubset NCIT_C63923 @default.
- NCIT_C128625 type Class @default.
- NCIT_C128625 isDefinedBy ncit.owl @default.
- NCIT_C128625 label "Caplacizumab" @default.
- NCIT_C128625 subClassOf NCIT_C128625 @default.
- NCIT_C128625 subClassOf NCIT_C1327 @default.
- NCIT_C128625 subClassOf NCIT_C1908 @default.
- NCIT_C128625 subClassOf NCIT_C1909 @default.
- NCIT_C128625 subClassOf NCIT_C78275 @default.